159 related articles for article (PubMed ID: 16995472)
1. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowskal H; Strzelczyk J; Janiak A; Malecka-Panas E
Hepatogastroenterology; 2006; 53(70):608-12. PubMed ID: 16995472
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
Int J Gastrointest Cancer; 2005; 35(1):33-41. PubMed ID: 15722572
[TBL] [Abstract][Full Text] [Related]
3. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
4. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis.
Löhr M; Müller P; Mora J; Brinkmann B; Ostwald C; Farré A; Lluis F; Adam U; Stubbe J; Plath F; Nizze H; Hopt UT; Barten M; Capellá G; Liebe S
Gastrointest Endosc; 2001 Jun; 53(7):734-43. PubMed ID: 11375580
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations.
Gansauge S; Schmid RM; Muller J; Adler G; Mattfeldt T; Beger HG
Br J Surg; 1998 Mar; 85(3):337-40. PubMed ID: 9529487
[TBL] [Abstract][Full Text] [Related]
6. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation.
Arvanitakis M; Van Laethem JL; Parma J; De Maertelaer V; Delhaye M; Devière J
Endoscopy; 2004 Jun; 36(6):535-42. PubMed ID: 15202051
[TBL] [Abstract][Full Text] [Related]
8. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
[TBL] [Abstract][Full Text] [Related]
9. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer.
Lu X; Xu T; Qian J; Wen X; Wu D
Chin Med J (Engl); 2002 Nov; 115(11):1632-6. PubMed ID: 12609076
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer].
Zhang J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779
[TBL] [Abstract][Full Text] [Related]
12. Mutations N34S and P55S of the SPINK1 gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects: a report from Finland.
Lempinen M; Paju A; Kemppainen E; Smura T; Kylänpää ML; Nevanlinna H; Stenman J; Stenman UH
Scand J Gastroenterol; 2005 Feb; 40(2):225-30. PubMed ID: 15764155
[TBL] [Abstract][Full Text] [Related]
13. [p53 gene mutations in in situ pancreatic adenocarcinomas].
Takagi T
Hokkaido Igaku Zasshi; 2001 May; 76(3):165-72. PubMed ID: 11481870
[No Abstract] [Full Text] [Related]
14. [An application value of detecting K-ras and p53 gene mutation in the stool and pure pancreatic juice for diagnosis of early pancreatic cancer].
Lu X; Xu T; Qian J
Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(17):1050-3. PubMed ID: 11758254
[TBL] [Abstract][Full Text] [Related]
15. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
Talar-Wojnarowska R; Malecka-Panas E
Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
[TBL] [Abstract][Full Text] [Related]
17. MTHFR C677T polymorphism in chronic pancreatitis and pancreatic adenocarcinoma.
Nisevic I; Dinic J; Nikolic A; Djordjevic V; Lukic S; Ugljesic M; Andjelic-Jelic M; Petrovic-Stanojevic N; Radojkovic D
Cell Biochem Funct; 2008 Aug; 26(6):659-63. PubMed ID: 18636416
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
Matsubayashi H; Canto M; Sato N; Klein A; Abe T; Yamashita K; Yeo CJ; Kalloo A; Hruban R; Goggins M
Cancer Res; 2006 Jan; 66(2):1208-17. PubMed ID: 16424060
[TBL] [Abstract][Full Text] [Related]
19. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO
Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229
[TBL] [Abstract][Full Text] [Related]
20. P53 mutation in advanced stage of primary myelodysplastic syndrome.
Tang JL; Tien HF; Lin MT; Chen PJ; Chen YC
Anticancer Res; 1998; 18(5B):3757-61. PubMed ID: 9854490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
